Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Schizophrenia

Treatments: Drug: Comparator: MK2637; Drug: Comparator: Placebo; Drug: MK2637; Drug: Comparator: Dextromethorphan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00934466

2637-008

MK2637-008

2009_608

Details and patient eligibility

About

This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(qEEG) readouts are also characterized with MK2637 and dextromethorphan.

Enrollment: 15 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject is right-handed
• Subject is in good health
• Subject is a nonsmoker

Exclusion criteria

• Subject works a night shift
• Subject has a history of any illness that might make participation in the study unsafe or confound the study results
• Subject has a history of head injury

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

15 participants in 5 patient groups, including a placebo group

1

Experimental group

Description:

MK2637 120 mg

Treatment:

Drug: MK2637

2

Experimental group

Description:

MK2637 50 mg

Treatment:

Drug: Comparator: MK2637

3

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Comparator: Placebo

4

Active Comparator group

Description:

Dextromethorphan 220 mg

Treatment:

Drug: Comparator: Dextromethorphan

Drug: Comparator: Dextromethorphan

5

Active Comparator group

Description:

Dextromethorphan 110 mg

Treatment:

Drug: Comparator: Dextromethorphan

Drug: Comparator: Dextromethorphan